Companies
Amgen
PharmaceuticalsThousand Oaks, CaliforniaAMGNAbout 31,500 employees
More about Amgen
Biotechnology company that develops and sells medicines for heart disease, bone loss, cancer, inflammation and rare diseases
Revenue
$36.8B
Fiscal 2025, up about 10%
Employees
About 31,500
As of December 2025
Stock
AMGN
Nasdaq
Headquarters
Thousand Oaks, California
CEO
Robert Bradway
Since 2012
BrandsRepatha, Prolia, Evenity, Tepezza, Enbrel, Blincyto
Current strategyExpanding existing medicines into new uses and moving pipeline drugs such as the obesity candidate MariTide through Phase 3 trials
Recent workforce changesAbout 40 roles cut in July 2026 and 22 former Horizon staff in March 2026
CompetitorsRegeneron, Gilead Sciences, Novartis
Related companiesRegeneron PharmaceuticalsGilead SciencesEli Lilly
Checked October 11, 2026 · Sources: sec.gov, sec.gov (2), fiercebiotech.com
No source-backed updates for Amgen yet. They appear here when a public report or filing covers the company.
No one has posted about Amgen yet. Be the first to post ›
Follow Amgen in a feed reader, no account needed: RSS feed